Enzyvant Announces Merger with Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonologyCARY, N.C.,...
Clinical Trial
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
Achievement Allows IND-enabling Studies in 1H’2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune DiseasesMedia Release...
AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis
-Next-generation PSGL-1 agonist antibody with clinically proven mechanism of action receives IND clearance- -Phase 1 clinical trial expected to launch...
TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in...
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
$500 Million Upfront Payment to Activate the Partnership for IvonescimabMenlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06,...
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
Professor Dr. med. Matthias Dobbelstein Professor Dr. med. Matthias DobbelsteinJerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals...
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome -- MELVILLE, N.Y., Dec....
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole
Strong support from high-quality new and existing investors provides capital for opelconazole development and pre-commercialization activities well beyond ongoing registration...
Agios Appoints Tsveta Milanova as Chief Commercial Officer
CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
Sernova Corp. Announces CEO Succession Plan and Expanded Management Team
The Company is recruiting a new CEO for its next stage of growth - Dr. Toleikis, President and CEO, to...
OnKure Therapeutics Appoints Robbie Alton, Pharm., as Vice President of Clinical Operations
BOULDER, Colo., Dec. 06, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation...
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
– Hepion Enrolls 60 F3 NASH Subjects in only 12 weeks, facilitated by AGILE 3+ non-invasive test – – Hepion,...
Allied Corp Successfully Executes on Another Sale & Export of Colombian Produced Cannabis Flower
KELOWNA, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more...
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm...
Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors
Matthew Hawryluk, Ph.D. POAI Board of DirectorsEAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is...
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE...
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with...